Opendata, web and dolomites

V-LAP SIGNED

A revolutionary direct, daily heart monitoring platform for long-term tailored treatment of Heart Disease patients.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 V-LAP project word cloud

Explore the words cloud of the V-LAP project. It provides you a very rough idea of what is the project "V-LAP" about.

invasively    clinicians    color    lap    monitor    blood    excess    people    decompensate    ing    min    external    organs    left    powered    30    lv    hospitalization    invasive    aged    measured    disruptive    coupling    indicator    sent    promptly    data    website    dyspnea    red    miniaturized    hf    quality    acute    sudden    daily    expenditure    diabetes    ac    unable    life    portfolio    device    worn    flow    free    events    day    filling    weeks    worsening    code    back    decreasing    adhf    prescription    threatening    provider    covered    procedure    levels    patients    green    global    detecting    swelling    collected    minimally    symptoms    worldwide    body    12    leg    healthcare    fluids    synchronize    yellow    catheter    hemodynamic    least    vectorious    total    tiredness    mobile    hospital    chronic    meet    patient    adjust    earliest    predict    mortality    heart    transition    28    glucose    completely    edema    patents    causes    battery    98    medications    ventricular    pressure    ineffective       implantable    takes    belt    pump    clothes    nhs    65    inductive   

Project "V-LAP" data sheet

The following table provides information about the project.

Coordinator
VECTORIOUS MEDICAL TECHNOLOGIES LTD 

Organization address
address: RAUL WALLENBERG 24
city: TEL AVIV JAFFA
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://vectoriousmedtech.com/
 Total cost 2˙621˙146 €
 EC max contribution 1˙834˙802 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VECTORIOUS MEDICAL TECHNOLOGIES LTD IL (TEL AVIV JAFFA) coordinator 1˙834˙802.00

Map

 Project objective

Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enough blood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swelling and tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate Heart Failure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% of total healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF, whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliest indicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’ disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV during patient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed through a minimally invasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: via inductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit which synchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/red color code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’ prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manage glucose levels in diabetes.

 Deliverables

List of deliverables.
Project webpage Websites, patent fillings, videos etc. 2019-07-22 17:27:08

Take a look to the deliverables list in detail:  detailed list of V-LAP deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Leor Perl, Elina Soifer, Jozef Bartunek, Dedi Erdheim, Friedrich Köhler, William T. Abraham, David Meerkin
A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience
published pages: , ISSN: 1937-5387, DOI: 10.1007/s12265-018-9856-3
Journal of Cardiovascular Translational Research ~13K Publications so far 2019-07-19

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "V-LAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "V-LAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

ARON (2020)

Assay-Ready Organ Network

Read More  

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More